Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles

Fang, Ronnie H.; Hu, Che Ming Jack; Chen, Kevin N H; Luk, Brian T.; Carpenter, Cody W.; Gao, Weiwei; Li, Shulin; Zhang, Dong Er; Lu, Weiyue; Zhang, Liangfang

doi:10.1039/c3nr03064d

Cited by 256 publications

(199 citation statements)

References 39 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…Currently, the paradigm in targeted nanomedicine revolves around high-throughput screening for ligand-receptor recognition and the subsequent nanoparticle functionalization with specific targeting molecules (47,48). With regard to type II immune hypersensitivity reactions, such a functionalization process could prove limited owing to the varying antigen specificities among pathological antibodies from patient to patient, such as in the case of AIHA (11,23,45).…”

Section: Discussionmentioning

confidence: 99%

Clearance of pathological antibodies using biomimetic nanoparticles

Copp¹,

Fang²,

Luk³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

254

183

View full text Add to dashboard Cite

Pathological antibodies have been demonstrated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction of healthy tissues and leading to considerable morbidity for the patient. Unfortunately, current treatments present significant iatrogenic risk while still falling short for many patients in achieving clinical remission. In the present work, we explored the capability of target cell membrane-coated nanoparticles to abrogate the effect of pathological antibodies in an effort to minimize disease burden, without the need for drug-based immune suppression. Inspired by antibody-driven pathology, we used intact RBC membranes stabilized by biodegradable polymeric nanoparticle cores to serve as an alternative target for pathological antibodies in an antibody-induced anemia disease model. Through both in vitro and in vivo studies, we demonstrated efficacy of RBC membrane-cloaked nanoparticles to bind and neutralize anti-RBC polyclonal IgG effectively, and thus preserve circulating RBCs.nanomedicine | immune therapy | type II hypersensitivity reaction | autoantibody

show abstract

Section: Discussionmentioning

confidence: 99%

Clearance of pathological antibodies using biomimetic nanoparticles

Copp¹,

Fang²,

Luk³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

254

183

View full text Add to dashboard Cite

show abstract

“…However, for cell membrane-coated nanoparticles, other functionalization strategies should be developed instead of chemical synthesis to protect the integrity of carbohydrates and proteins located on the cell membranes. Fang et al [41] developed a non-destructive strategy to introduce targeting ligands to RBCNPs, which is so-called lipid insertion. Targeting ligands was first conjugated to lipid molecules and then inserted into the RBC membranes.…”

Section: Tumor-specific Targeting Via Lipid Insertionmentioning

confidence: 99%

Cell membrane-coated nanoparticles for tumor-targeted drug delivery

Chai

2017

Sci. China Mater.

Self Cite

View full text Add to dashboard Cite

Nanoparticles can be enriched at tumor site and improve the therapeutic efficacy of many chemotherapy drugs with the well-known enhanced permeability and retention (EPR) effect. While conventional preparations of materials for nanoscale drug delivery system mainly focused on chemical synthesis, recently the combination of synthetic carrier and natural biomimetic carrier has gained more and more attention. As a new generation of biomimetic nanoparticles, cell membrane-coated nanoparticles combine the complex biological functions of natural membranes and the physicochemical properties of synthetic nanomaterials for a more effective drug delivery. Herein, we briefly review the recent advances on cell membrane-coated nanoparticles for tumor-targeted drug delivery via the prolonging systemic circulation lifetime and the active targeting effect. Since the preferential accumulation of cell membrane-coated nanoparticles in tumor site, they are able to improve the therapeutic efficacy of conventional chemotherapy drugs in antitumor treatment as well as to reduce the systemic toxicity. We also introduce a systematic targeted strategy for the promising application of this platform on brain tumors.

show abstract

“…Furthermore, immunoevasion led by membrane coating made the RBCm-GA/PLGA group slightly better than the GA/PLGA group. In future work, achieving a specific active target by utilizing specific membranes derived from selected cells, 36 such as cancer cells, [37][38][39][40] or via targeting ligands inserted into membranes 41,42 can be designed to build a nanocarrier with better antitumor effect.…”

mentioning

confidence: 99%

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

Zhang

Yang

et al. 2017

IJN

View full text Add to dashboard Cite

Gambogic acid (GA) is expected to be a potential new antitumor drug, but its poor aqueous solubility and inevitable side effects limit its clinical application. Despite these inhe rent defects, various nanocarriers can be used to promote the solubility and tumor targeting of GA, improving antitumor efficiency. In addition, a cell membrane-coated nanoparticle platform that was reported recently, unites the customizability and flexibility of a synthetic copolymer, as well as the functionality and complexity of natural membrane, and is a new synthetic biomimetic nanocarrier with improved stability and biocompatibility. Here, we combined poly(lactic- co -glycolic acid) (PLGA) with red blood-cell membrane (RBCm), and evaluated whether GA-loaded RBCm nanoparticles can retain and improve the antitumor efficacy of GA with relatively lower toxicity in colorectal cancer treatment compared with free GA. We also confirmed the stability, biocompatibility, passive targeting, and few side effects of RBCm-GA/PLGA nanoparticles. We expect to provide a new drug carrier in the treatment of colorectal cancer, which has strong clinical application prospects. In addition, the potential antitumor drug GA and other similar drugs could achieve broader clinical applications via this biomimetic nanocarrier.

show abstract

Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles

Cited by 256 publications

References 39 publications

Clearance of pathological antibodies using biomimetic nanoparticles

Clearance of pathological antibodies using biomimetic nanoparticles

Cell membrane-coated nanoparticles for tumor-targeted drug delivery

Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment

Contact Info

Product

Resources

About